Ionis partner Roche's sefaxersen cuts proteinuria 43.1% versus placebo in Phase 3 IgAN trial
Bitget2026/10/23 17:43- Ionis partner Roche reported sefaxersen reduced proteinuria 43.1% versus placebo at 37 weeks in the Phase 3 IMAgINATION trial for IgA nephropathy.
- The reduction was statistically significant (95% confidence interval: 32.5%-52%; P<0.0001), with consistent treatment effects across all prespecified subgroups.
- Sefaxersen, an investigational monthly injection designed for self-administration, was well tolerated, with no new safety signals.
- The blinded trial will continue to assess kidney function at week 105; Roche plans to share results with health authorities.
- The licensing agreement provides eligibility for regulatory and sales milestone payments, plus tiered royalties on sefaxersen net sales.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Updated version 2-BP reports the highest net profit in at least five years
AstraZeneca (AZN.US) Q3 profit growth surpasses expectations, driven mainly by oncology drugs
AstraZeneca (AZN.US) released its Q3 2026 results on October 30th. At constant exchange rates (CER), total revenue for the quarter increased by 7% year-on-year to $16.209 billions.
BP.US Q3 profits soar to 18-year high: Refining business becomes 'money-printing machine', CEO's reforms encounter strong tailwind
Benefiting from a surge in refining profit margins, BP's quarterly profit jumped to its highest level in 18 years.
Australian Dollar: Bias shifts back to neutral against US Dollar – UOB
Crypto prices
More
